L’ONDCP réduit considérablement les estimations de production potentielle de cocaïne en Bolivie
Le dernier rapport de l’Office américain sur la politique nationale de contrôle des drogues (ONDCP) a gonflé les chiffres de production de cocaïne en Bolivie, entrainant une modification des statistiques régionales.
Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.
Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.
On July 9, the US Office of National Drug Control Policy (ONDCP) published its estimates of potential cocaine production in the Andes, citing a significant region-wide decrease from 2011 to 2012. The largest reduction reported occurred in Bolivia: -18%, compared to -5% in Peru and -8% in Colombia. Yet the ONDCP attributed the regional reduction to the “strengthened U.S.-Colombia partnership forged over the past decade and the increased commitment to counternarcotics cooperation and citizen security from President Ollanta Humala and the Government of Peru” as well as other developments in those two countries. There was no mention of Bolivia.
Unexplained Change in Figures
Although they failed to provide any explanation, the same ONDCP press release reported Bolivia’s potential cocaine production for 2011 at 190 metric tons—instead of the whopping 265 metric tons for 2011 reported by the same office a year earlier. The estimates drew harsh criticism from the international community, as well as AIN and the Washington Office on Latin America, for inflating figures for Bolivia and downplaying Colombia’s cocaine production. This is especially hard to swallow considering Colombia’s coca crop is considerably larger, and both countries employ similar processing methods.
Using the original figure, the decline in cocaine production from 2011-2012 would be -41% —a dramatic change. In fact, the ONDCP webpage retroactively reduced the previous five years of potential cocaine production figures from those published on the same page in September 2012.
Read here the full article.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.